In multiple randomized clinical studies, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly improved visualization and contrast enhancement of CNS lesions when compared with Gadavist®, Dotarem®, Magnevist®, and OmniscanTM.1-4
Figure 1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Gadavist*
In the MERIT study, a multicenter, double-blind, randomized, intraindividual cross-over study of 123 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly higher lesion enhancement. In the image above, a 58-year-old woman with metastasis from melanoma underwent MR imaging for definite staging of metastatic disease. T1 GRE images reveal a metastasis in the right superior frontal gyrus. However, the lesion appears larger and shows more conspicuous enhancement with MultiHance (gadobenate dimeglumine) injection, 529 mg/mL than with Gadavist.1
Figure 2. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Dotarem*
In the BENEFIT study, a multicenter, double-blind, randomized, intraindividual cross-over study of 177 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly higher lesion enhancement. In the image above, a 53-year-old man with left parietal glioblastoma underwent MR imaging. An aggressive-appearing mass with inhomogeneous enhancement showed greater lesion enhancement on images obtained with MultiHance (gadobenate dimeglumine) injection, 529 mg/mL.2
Figure 3: MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Magnevist*
In the Maravilla, et al. study, a multicenter, double-blind, randomized, intraindividual cross-over study of 157 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL demonstrated significantly higher lesion enhancement. In the image above, a 51-year-old woman with metastatic lung cancer underwent MR imaging. Administration of MultiHance (gadobenate dimeglumine) injection, 529 mg/mL revealed meningeal carcinomatosis over the right frontal lobe and 2 additional metastatic nodules in the left frontal (upper arrow) and right occipital (lower arrow) areas not seen with Magnevist.3
Figure 4: MultiHance (gadobenate dimeglumine) injection, 529 mg/mL vs. Omniscan*
In the ENHANCE study, a multicenter, double-blind, randomized, intraindividual cross-over study of 138 patients, MultiHance (gadobenate dimeglumine) injection, 529 mg/mL resulted in significantly higher lesion enhancement. In the image above, a 55-year-old woman with recurrent glioblastoma underwent MR imaging. T1 GRE images show more conspicuous enhancement (arrow) in the right posterior temporal lobe with MultiHance (gadobenate dimeglumine) injection, 529 mg/mL.4
*These are representative images from reference studies, individual results may vary.
All trademarks and registered trademarks are the property of their respective owners.
"The greater definition and delineation of lesions combined with the increased potential for detection of small or otherwise poorly enhancing lesions with MultiHance might have considerable impact in terms of selecting the appropriate medical or surgical treatment to assure maximum benefit and improved patient outcomes." — Kuhn MJ, et al. J Neurosurg 20075
1. Seidl Z, Vymazal J, Mechl M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol. 2012;33(6):1050–1058. 2. Vaneckova M, Herman M, Smith MP, et al. The benefits of high relaxivity for brain tumor imaging: results of a multicenter intraindividual crossover comparison of gadobenate dimeglumine with gadoterate meglumine (The BENEFIT Study). AJNR Am J Neuroradiol. 2015;36(9):1589–1598. 3. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology. 2006;240(2):389–400. 4. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol. 2008;29(9):1684–1691. 5. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg. 2007 Apr;106(4):557-566.
